Psychedelics research at Imperial College enters a new phase
The second phase to be exact. This year the newly minted Centre for Psychedelic Research at Imperial College London began conducting a first-of-its-kind phase II clinical trial designed to test how effective the hallucinogenic compound psilocybin is at treating patients with major depressive disorder versus a current prescription antidepressant, escitalopram.